As Dr. Peter Doshi
explains in the
ritish Medical Journal : “With 20 times more suspected than confirmed cases, this category of disease cannot be ignored simply because there was no positive PCR test result.” Bundling in both the suspected and confirmed cases, Doshi notes, would drop “the 95% relative risk-reduction figure down to only 19%.”
A relative risk reduction of 19 percent is far below the 50 percent effectiveness threshold for authorization set by regulators. And even the 19 percent tally assumes that the data are veridical.
Bluntly speaking, what these interested participants are doing is eliminating unfavorable factors. The Defender (Children’s Health Defense) points out that when one does the real math, the
Pfizer clinical trial numbers showed that:
“the risk reduction in absolute terms [was] only 0.7%, from an already very low risk of 0.74% [in the placebo group] to a minimal risk of 0.04% [in the vaccine group].” Dividing 0.7 by 0.74 is the mathematical calculation that produced the touted “95% effective” number. The result has been corroborated by the quality virological journal Vaccines, which reports that the absolute risk reduction is less than 1 percent. Clearly, Pfizer cooked the books. The math was right,
so far as it went —which was not very far—but the statistical implications were misleading.
What cannot be denied is that, by any metric, vaccine efficacy remains low. It seems evident that data collection is often intended to paint the wished-for statistical canvas.